AT&T reported $32.96 billion in revenue for the quarter, missing Street estimates of $33.25 billion.
The aerospace giant also raised its full-year guidance.
Sales of Biogen Idec's new multiple sclerosis drug Tecfidera fell short of Wall Street estimates for the first time. Its shares fell nearly 3 percent.
Get the best of CNBC in your inbox